Clinical Trial Update: A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002) [Phase 1]

View source ↗

Summary

The Phase 1 study of MK-5823 (NCT01614782) in overweight or obese participants, including individuals with Type 2 Diabetes Mellitus, was terminated. The update …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• MK-5823

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: TERMINATED